Bozkurt Murat Fani
Department of Nuclear Medicine, Hacettepe University Faculty of Medicine, TR-06100 Ankara, Turkey.
Nucl Med Mol Imaging. 2019 Feb;53(1):11-13. doi: 10.1007/s13139-018-0564-3. Epub 2018 Dec 15.
Nuclear theranostics functions as a bridge which connects targeted diagnosis to targeted therapy, just like Turkey functions as a geographical bridge which connects Asia to Europe. This unique geographical site of the country plays an important role with regard to introduction of novel scientific and technologic improvements, which originate from one continent to another, in the era of accelerated information. The first nuclear medicine practice in Turkey started in the beginning of 1950s with the first radioiodine treatment, which actually was a debut for nuclear theranostics in Turkey, years before many other countries in the world. For the time being, along with radioiodine treatment, many other theranostic applications such as I-131 MIBG treatment, Lu-177/Y-90 DOTA peptide treatment, Lu-177 PSMA treatment, Y-90 microsphere treatment, and bone palliative treatment are being performed in many centers countrywide. As science and technology improves, novel theranostic applications are eagerly awaited to be introduced in near future. This paper summarizes the story of nuclear theranostics in Turkey and aims to give an overview on the current status of theranostic applications in Turkey.
核诊疗学就像一座连接靶向诊断与靶向治疗的桥梁，土耳其则像是连接亚洲与欧洲的地理桥梁。在信息加速发展的时代，该国独特的地理位置对于源自一个大陆并传播到另一个大陆的新型科技进步的引入发挥着重要作用。土耳其的首次核医学实践始于20世纪50年代初，当时进行了首例放射性碘治疗，实际上这在土耳其是核诊疗学的首次亮相，比世界上许多其他国家都要早很多年。目前，除了放射性碘治疗外，全国许多中心还在开展许多其他诊疗应用，如I-131 MIBG治疗、Lu-177/Y-90 DOTA肽治疗、Lu-177 PSMA治疗、Y-90微球治疗以及骨姑息治疗。随着科技的进步，人们热切期待在不久的将来引入新的诊疗应用。本文总结了土耳其核诊疗学的发展历程，并旨在概述土耳其诊疗应用的现状。
